(secondQuint)Safety and Efficacy of the SurVeil Drug-Coated Balloon.

 TRANSCEND is a prospective, multi-center, single-blind, randomized, controlled, noninferiority clinical trial.

 The trial will randomize approximately 446 subjects with symptomatic PAD due to stenoses of the femoral and/or popliteal arteries.

 Subjects meeting eligibility criteria will be randomized 1:1 to treatment with either the SurVeil DCB or the IN.

PACT Admiral DCB, and followed for 60 months.

.

 Safety and Efficacy of the SurVeil Drug-Coated Balloon@highlight

To demonstrate the safety and efficacy of the SurVeil Drug-Coated Balloon (DCB) for treatment of subjects with symptomatic peripheral artery disease (PAD) due to stenosis of the femoral and/or popliteal arteries.

